Pages that link to "Q38425937"
Jump to navigation
Jump to search
The following pages link to Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. (Q38425937):
Displaying 50 items.
- Therapeutic options for management of endometrial hyperplasia (Q26783569) (← links)
- Targeting the mTOR/4E-BP Pathway in Endometrial Cancer (Q27010539) (← links)
- Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations (Q27853244) (← links)
- Chemoresistance and targeted therapies in ovarian and endometrial cancers (Q28073246) (← links)
- Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas (Q28074769) (← links)
- Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? (Q33633962) (← links)
- Promising novel therapies for the treatment of endometrial cancer (Q33920661) (← links)
- Controversies in the management of endometrial carcinoma (Q33960894) (← links)
- Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis (Q34272887) (← links)
- A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. (Q34781699) (← links)
- Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study (Q35023418) (← links)
- Therapeutic advances in women's cancers (Q35418973) (← links)
- Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor (Q35870242) (← links)
- Personalized therapy in endometrial cancer: Challenges and opportunities (Q35911350) (← links)
- KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer (Q36451726) (← links)
- A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study (Q36980484) (← links)
- Personalized care in uterine cancer. (Q37006856) (← links)
- Somatic Deletions of the PolyA Tract in the 3′ Untranslated Region of Epidermal Growth Factor Receptor Are Common in Microsatellite Instability–High Endometrial and Colorectal Carcinomas (Q37252262) (← links)
- The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies (Q37349623) (← links)
- Systemic therapy for recurrent endometrial cancer: a review of North American trials (Q37546032) (← links)
- Recent Advances in Endometrial Cancer (Q37620470) (← links)
- Small-molecule inhibitors of the human epidermal receptor family. (Q37638679) (← links)
- Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers (Q37671783) (← links)
- Treatment options for advanced endometrial carcinoma (Q37707615) (← links)
- Emerging drugs in endometrial cancers (Q37786618) (← links)
- Emerging therapeutic targets in endometrial cancer (Q37827340) (← links)
- The biological and therapeutic relevance of mRNA translation in cancer (Q37848652) (← links)
- The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer (Q37929371) (← links)
- New Biologic Agents for the Treatment of Gynecologic Cancers (Q37975730) (← links)
- Medical therapy of endometrial cancer: current status and promising novel treatments. (Q37996079) (← links)
- Contemporary management of endometrial cancer (Q37996608) (← links)
- New and potential clinical applications of KRAS as a cancer biomarker (Q38089885) (← links)
- Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. (Q38095600) (← links)
- Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option (Q38114478) (← links)
- Recent and current Phase II clinical trials in endometrial cancer: review of the state of art. (Q38203354) (← links)
- Update on prognostic markers for endometrial cancer (Q38222517) (← links)
- Endometrial cancer: redefining the molecular-targeted approach (Q38454955) (← links)
- An update on the current pharmacotherapy for endometrial cancer (Q38656675) (← links)
- Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. (Q38687847) (← links)
- New Targeted Agents in Endometrial Cancer: Are We Really Making Progress? (Q38753038) (← links)
- Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings (Q38895754) (← links)
- Endometrial Carcinoma: Specific Targeted Pathways. (Q39026766) (← links)
- Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer. (Q39269339) (← links)
- Targeted endometrial cancer therapy as a future prospect (Q39454208) (← links)
- EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells (Q39467200) (← links)
- High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion (Q39536386) (← links)
- MUC1 stimulates EGFR expression and function in endometrial cancer. (Q39840036) (← links)
- New therapies for advanced, recurrent, and metastatic endometrial cancers. (Q47103210) (← links)
- Erlotinib: applications in therapy and current status of research. (Q54777001) (← links)
- Immunotherapy in endometrial cancer: new scenarios on the horizon (Q64270860) (← links)